TW202434243A - 含有內含拓普替康或其鹽之脂質體組成物及ｄｎａ損傷修復抑制劑之組合醫藥 - Google Patents

含有內含拓普替康或其鹽之脂質體組成物及ｄｎａ損傷修復抑制劑之組合醫藥 Download PDF

Info

Publication number
TW202434243A
TW202434243A TW112144902A TW112144902A TW202434243A TW 202434243 A TW202434243 A TW 202434243A TW 112144902 A TW112144902 A TW 112144902A TW 112144902 A TW112144902 A TW 112144902A TW 202434243 A TW202434243 A TW 202434243A
Authority
TW
Taiwan
Prior art keywords
dna damage
drug
topotecan
inhibitor
liposome composition
Prior art date
Application number
TW112144902A
Other languages
English (en)
Chinese (zh)
Inventor
下山晉
岡田健
森幹永
Original Assignee
日商富士軟片股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商富士軟片股份有限公司 filed Critical 日商富士軟片股份有限公司
Publication of TW202434243A publication Critical patent/TW202434243A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112144902A 2022-11-21 2023-11-21 含有內含拓普替康或其鹽之脂質體組成物及ｄｎａ損傷修復抑制劑之組合醫藥 TW202434243A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022185972 2022-11-21
JP2022-185972 2022-11-21

Publications (1)

Publication Number Publication Date
TW202434243A true TW202434243A (zh) 2024-09-01

Family

ID=91195598

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112144902A TW202434243A (zh) 2022-11-21 2023-11-21 含有內含拓普替康或其鹽之脂質體組成物及ｄｎａ損傷修復抑制劑之組合醫藥

Country Status (6)

Country Link
US (1) US20250268827A1 (https=)
EP (1) EP4623915A4 (https=)
JP (1) JPWO2024111564A1 (https=)
CN (1) CN120225196A (https=)
TW (1) TW202434243A (https=)
WO (1) WO2024111564A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
JP7042739B2 (ja) * 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
EP4647126A3 (en) * 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
EP3423048A4 (en) * 2016-02-29 2019-10-23 Synta Pharmaceuticals Corp. COMBINATION THERAPY FOR THE TREATMENT OF EGG CANCER
RU2734900C1 (ru) 2017-03-31 2020-10-26 Фуджифилм Корпорэйшн Липосомальная композиция и фармацевтическая композиция
PL3811931T3 (pl) 2018-06-20 2024-11-18 Fujifilm Corporation Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
TWI837189B (zh) 2018-10-01 2024-04-01 日商富士軟片股份有限公司 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥
JPWO2022250013A1 (https=) * 2021-05-24 2022-12-01

Also Published As

Publication number Publication date
EP4623915A4 (en) 2026-04-01
WO2024111564A1 (ja) 2024-05-30
JPWO2024111564A1 (https=) 2024-05-30
CN120225196A (zh) 2025-06-27
EP4623915A1 (en) 2025-10-01
US20250268827A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
CN103083239B (zh) 一种蟾毒灵脂质体及其制备方法和应用
EP3372232B1 (en) Tumor therapeutic agent comprising gemcitabine liposome composition and kit
TWI837189B (zh) 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥
TW200936182A (en) Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation
ES2984148T3 (es) Medicamento de combinación que contiene una composición liposómica que encapsula un fármaco y un inhibidor de punto de control inmunitario
TW202207904A (zh) 用於治療癌症及癌症抗藥性之脂質體調配物
RU2571283C2 (ru) Парентеральные составы производных элацитарабина
WO2016024595A1 (ja) エピルビシン複合化ブロック共重合体と、抗癌剤とを含むミセル、及び当該ミセルを含む癌又は耐性癌、転移癌の治療に適用可能な医薬組成物
Hu et al. Enhanced uptake and improved anti-tumor efficacy of doxorubicin loaded fibrin gel with liposomal apatinib in colorectal cancer
TW202434243A (zh) 含有內含拓普替康或其鹽之脂質體組成物及ｄｎａ損傷修復抑制劑之組合醫藥
HK40122907A (zh) 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物
WO2022250013A1 (ja) 抗腫瘍剤
EP3395370B1 (en) Liposome and liposome composition
AU2021249949B2 (en) Antitumor agent
TW202203943A (zh) 抗腫瘤劑
HK40102143A (zh) 抗肿瘤剂
HK40086650A (zh) 用於治疗癌症和癌症耐药性的脂质体制剂
HK40045737A (en) Combination medicine comprising drug-encapsulating liposome composition and platinum preparation
HK40041777A (en) Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor
HK40041777B (en) Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor
HK1186381A (en) Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation
HK1146469B (en) Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation